Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Seyed A Moghadasi"'
Autor:
Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe, Ju-Yi Peng, Bernhard Sprenger, Xi He, Seyed Arad Moghadasi, Lisa Maria Egger, Jakob Fleischmann, Matteo Pavan, Davide Bassani, Silvia Menin, Stefanie Rauch, Laura Krismer, Anna Sauerwein, Anne Heberle, Toni Rabensteiner, Joses Ho, Reuben S Harris, Eduard Stefan, Rainer Schneider, Theresia Dunzendorfer-Matt, Andreas Naschberger, Dai Wang, Teresa Kaserer, Stefano Moro, Dorothee von Laer, Emmanuel Heilmann
Publikováno v:
PLoS Pathogens, Vol 20, Iss 9, p e1012522 (2024)
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2 main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available
Externí odkaz:
https://doaj.org/article/8a2d120a7782489fb1d69e04556b8418
Autor:
Renee Delgado, Jyoti Vishwakarma, Seyed Arad Moghadasi, Yuka Otsuka, Justin Shumate, Ashley Cuell, Megan Tansiongco, Christina B. Cooley, Yanjun Chen, Agnieszka Dabrowska, Rahul Basu, Paulina Duhita Anindita, Dahai Luo, Peter I. Dosa, Daniel A. Harki, Thomas Bannister, Louis Scampavia, Timothy P. Spicer, Reuben S. Harris
Publikováno v:
SLAS Discovery, Vol 29, Iss 6, Pp 100181- (2024)
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2, SARS2) is responsible for the COVID-19 pandemic and infections that continue to affect the lives of millions of people worldwide, especially those who are older and/or immunocompromised. Th
Externí odkaz:
https://doaj.org/article/c4f7ebe12cd3480bb2ae4720b580813c
Autor:
Ravikumar Jimmidi, Srinivas Chamakuri, Shuo Lu, Melek Nihan Ucisik, Peng-Jen Chen, Kurt M. Bohren, Seyed Arad Moghadasi, Leroy Versteeg, Christina Nnabuife, Jian-Yuan Li, Xuan Qin, Ying-Chu Chen, John C. Faver, Pranavanand Nyshadham, Kiran L. Sharma, Banumathi Sankaran, Allison Judge, Zhifeng Yu, Feng Li, Jeroen Pollet, Reuben S. Harris, Martin M. Matzuk, Timothy Palzkill, Damian W. Young
Publikováno v:
Communications Chemistry, Vol 6, Iss 1, Pp 1-10 (2023)
Abstract The development of SARS-CoV-2 main protease (Mpro) inhibitors for the treatment of COVID-19 has mostly benefitted from X-ray structures and preexisting knowledge of inhibitors; however, an efficient method to generate Mpro inhibitors, which
Externí odkaz:
https://doaj.org/article/aab44f4c21884a5ab19d7b954a87359d
Autor:
Ashley A. Auerbach, Jordan T. Becker, Sofia N. Moraes, Seyed Arad Moghadasi, Jolene M. Duda, Daniel J. Salamango, Reuben S. Harris
Publikováno v:
mSphere, Vol 7, Iss 6 (2022)
ABSTRACT APOBEC3B is an innate immune effector enzyme capable of introducing mutations in viral genomes through DNA cytosine-to-uracil editing. Recent studies have shown that gamma-herpesviruses, such as Epstein-Barr virus (EBV), have evolved a poten
Externí odkaz:
https://doaj.org/article/a41bf03117264cc4867ed3105146f18f
Autor:
Sofia N Moraes, Jordan T Becker, Seyed Arad Moghadasi, Nadine M Shaban, Ashley A Auerbach, Adam Z Cheng, Reuben S Harris
Publikováno v:
eLife, Vol 11 (2022)
Viruses have evolved diverse mechanisms to antagonize host immunity such as direct inhibition and relocalization of cellular APOBEC3B (A3B) by the ribonucleotide reductase (RNR) of Epstein-Barr virus. Here, we investigate the mechanistic conservation
Externí odkaz:
https://doaj.org/article/62fa70d70b3b4647b32f816eb1942dd8
Autor:
Seyed Arad Moghadasi, Morgan A. Esler, Yuka Otsuka, Jordan T. Becker, Sofia N. Moraes, Constance B. Anderson, Srinivas Chamakuri, Christopher Belica, Chloe Wick, Daniel A. Harki, Damian W. Young, Louis Scampavia, Timothy P. Spicer, Ke Shi, Hideki Aihara, William L. Brown, Reuben S. Harris
Publikováno v:
mBio, Vol 13, Iss 3 (2022)
ABSTRACT The main protease, Mpro, of SARS-CoV-2 is required to cleave the viral polyprotein into precise functional units for virus replication and pathogenesis. Here, we report quantitative reporters for Mpro function in living cells in which protea
Externí odkaz:
https://doaj.org/article/5f8de00bdfcb488bbae8b0acf0272a23
Autor:
Brett D. Anderson, Terumasa Ikeda, Seyed Arad Moghadasi, Amber St. Martin, William L. Brown, Reuben S. Harris
Publikováno v:
Retrovirology, Vol 15, Iss 1, Pp 1-11 (2018)
Abstract Background The APOBEC3 (A3) family of DNA cytosine deaminases provides an innate barrier to infection by retroviruses including HIV-1. A total of five enzymes, A3C, A3D, A3F, A3G and A3H, are degraded by the viral accessory protein Vif and e
Externí odkaz:
https://doaj.org/article/7f8c1f7bd80544c3a7e4d7d3c3f3ac67
Autor:
Daniel J. Salamango, Terumasa Ikeda, Seyed Arad Moghadasi, Jiayi Wang, Jennifer L. McCann, Artur A. Serebrenik, Diako Ebrahimi, Matthew C. Jarvis, William L. Brown, Reuben S. Harris
Publikováno v:
Cell Reports, Vol 29, Iss 5, Pp 1057-1065.e4 (2019)
Summary: HIV-1 Vif hijacks a cellular ubiquitin ligase complex to degrade antiviral APOBEC3 enzymes and PP2A phosphatase regulators (PPP2R5A–E). APOBEC3 counteraction is essential for viral pathogenesis. However, Vif also functions through an unkno
Externí odkaz:
https://doaj.org/article/c1e98fbb6c6d4901afc605ca1d57b854
Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (Mpro) variants and a robust cell-based assay are used to compare the resistance p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e06625227bf166e81702f0417e518ffb
https://doi.org/10.1101/2023.02.25.530000
https://doi.org/10.1101/2023.02.25.530000
Autor:
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, Andre Volland, Claudia Ascher, Alexander Kurt Hermann Weiss, David Bante, Reuben S. Harris, Stefano Moro, Bernhard Rupp, Luis Martinez-Sobrido, Dorothee von Laer
Publikováno v:
Science Translational Medicine. 15
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL pro that has been licensed for clinical use. To identify mutations that confer re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0448e7f05cc1a918bd239d187ffc59bb
https://doi.org/10.1126/scitranslmed.abq7360
https://doi.org/10.1126/scitranslmed.abq7360